Submit Deal

ALEXANDRIA VENTURE INVESTMENTS

HQ - Pasadena

Summary

Alexandria Venture Investments provides long-term strategic investment capital to innovative life science, technology, and agtech entities developing breakthrough technologies and therapies.

Deals Overview

Total Deals54

Valued Deals54

Total Value£ 7.99 B

Avg. Deal Size£ 148 M

Market Context

Senior Management

Peter Moglia
CEO
Stephen Richardson
CEO
Peter M. Moglia
CEO and Co-CIO

Sort

insitro

HQ - United States

Medical Services

26 May 2020

Investment Date

£ 116 M

Deal Value

compass therapeutics llc

HQ - United States

Biotechnology

23 Jun 2020

Investment Date

100%

Stake

£ 48 M

Deal Value

neurogene inc

HQ - United States

Biotechnology

16 Dec 2020

Investment Date

£ 85 M

Deal Value

humacyte

HQ - United States

Biotechnology

26 Aug 2021

Investment Date

100%

Stake

£ 618 M

Deal Value

c2i genomics

HQ - United States

Biotechnology

15 Apr 2021

Investment Date

£ 72 M

Deal Value

boundless bio

HQ - United States

Biotechnology

28 Apr 2021

Investment Date

£ 75 M

Deal Value

jasper therapeutics inc

HQ - United States

Biotechnology

24 Sep 2021

Investment Date

100%

Stake

£ 350 M

Deal Value

inari

HQ - United States

Food Products

12 May 2021

Investment Date

£ 147 M

Deal Value

effector therapeutics

HQ - United States

Biotechnology

25 Aug 2021

Investment Date

100%

Stake

£ 296 M

Deal Value

mnemo therapeutics

HQ - France

Biotechnology

16 Jun 2021

Investment Date

£ 63 M

Deal Value

umoja biopharma

HQ - United States

Biotechnology

15 Jun 2021

Investment Date

£ 148 M

Deal Value

vividion therapeutics

HQ - United States

Biotechnology

19 Aug 2021

Investment Date

100%

Stake

£ 1.44 B

Deal Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy